 NEW YORK, July 12, 2021 GLOBE NEWSWIRE -- Scopus BioPharma Inc. Nasdaq: SCPS, a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical needs, today announced a new management appointment following its acquisition of Olimmune Inc., a leading immunotherapy company. Alan Horsager, Ph.D., President and Chief Executive of Olimmune, was appointed President of Scopus with responsibility for overseeing the development of the Companys rapidly expanding immuno-oncology pipeline. 